We have analysed the dose-response curve for halothane and isoflurane according to the Monod-Wyman-Changeux (MWC) model. This model describes the nature of the physiological data reported by Wakamori, Ikemoto and Akaike for inhibitory CI currents induced by GABA or glycine in dissociated rat brain neurones and by Herrington and colleagues for Ca 2; currents in clonal pituitary cells. With some assumptions on the difference in response to anaesthetics between patients, the model is applicable in vivo, and it also describes well the human doseresponse curve for isoflurane reported by Mather, Raftery and Prys-Roberts. However, the steeply sigmoidal dose-response curve in humans for halothane presented by deJong and Eger is difficult to understand with the same model, because it gives rise to unrealistic MWC variables. (Br. J. Anaesth. 1996;77:517-521) Key words Anaesthetics volatile, halothane. Anaesthetics volatile, isoflurane. Model, mathematical.
The mechanism of action of anaesthetics is still controversial. Because the potencies of volatile anaesthetics increase in proportion to their solubility in oil, it has been proposed that general anaesthetics act by disturbing the structure or dynamic properties of the lipid-bilayer portions of nerve membranes. Such perturbations, however, were found to be extremely small at concentrations used clinically. In contrast, physiological studies indicate that specific interactions occur with membrane proteins, such as receptors and ligand-gated ion channels, and these receptors have been proposed as sites of anaesthetic action 1 2 . For example, the ␥-aminobutyric acid (GABA) receptor is very sensitive to most volatile anaesthetics; inhalation agents, halothane and enflurane, at surgical concentrations, markedly enhanced inhibitory currents induced by GABA, causing a shift in the dose-response curve (response of current to GABA concentration) to lower GABA concentrations 3 . Moss, Franks and Lieb demonstrated that the activity of a soluble lipid-free enzyme, firefly luciferase, was inhibited by a range of anaesthetics at concentrations close to their respective EC50 values 4 . Some agents with optical isomers show stereoselectivity 5 . This suggests that anaesthetics may act by binding directly to proteins.
Changeux has reviewed the most thorough study on the nicotinic acetylcholine receptor, and demonstrated the allosteric nature of ligand-gated ion channels 6 . The dose-response curve determined experimentally suggests binding of anaesthetic molecules to a receptor protein molecule. In this article, we have analysed the behaviour of anaesthetics in the framework of the Monod-Wyman-Changeux (MWC) model 7 , which has been used successfully to understand the behaviour of allosteric protein molecules [8] [9] [10] . We refer to the electrophysiological data reported by Wakamori, Ikemoto and Akaike 3 and by Herrington and colleagues 11 to see how well the MWC model works. We then analyse the data on anaesthetic potency for humans presented by deJong and Eger 12 and by Mather, Raftery and PrysRoberts 13 on the basis of the MWC model.
Methods

IN VITRO DOSE-RESPONSE
According to the MWC model 7 , we assume that a receptor protein molecule has two different conformations, R and T, each of which contains r binding sites for a ligand X; the sites are similar and independent. The whole system is assumed to be in equilibrium. The R form is termed anaestheticsensitive, because anaesthetic molecules (the ligand) bind more readily to the R form of the receptor molecule than to the T form. The binding equilibrium constant KT for a site on the T-form molecules is usually much smaller than that for the R-form molecules, KR, so that the ratio c (:KT/KR) is much smaller than unity. However, in the absence of anaesthetic ([X]:0), most of the receptor molecules are in the T form; the equilibrium constant for the R T transition, L(:
, is usually much greater than unity. Hence there is near-zero response at low concentrations of ligand. As the concentration of ligand increases, the ligand binds mainly to the R-form molecules giving combined molecules RX, RX2, RX3, as one, two and three of the receptor sites on the R-form molecules become occupied with ligand X. In addition, there are some TX, TX2, TX3, molecules, and the numbers of the RXi molecules is equal to that of the TXi molecules (i:0, 1, 2,..., r) at the ligand concentration giving 50% response. Eventually, at high concentrations of X, almost all the receptor molecules are in the RXi form and the response is maximal. At all concentrations of X, the response, expressed as a fraction Z of the maximum, is considered to be equal to the amount of RXi molecules as a fraction of the total RXi and TXi molecules. The MWC formulation (appendix) gives the fractional response Z as follows:
where x:ligand concentration at receptor sites:
. The MWC variables of the equilibrium process, KR, c, L and the number of sites r, should be determined from reasonable fitting to the experimental dose-response data.
In practice, we determined those variables using the Hill approximation. The experimental doseresponse curve is conventionally expressed by:
where n:the Hill coefficient and is a measure of cooperativity (n91 is the condition of cooperativity).
When n is large, the curve shows high cooperativity and is steep in shape. Constant xm is the x value at a half-maximal point ( y:50%). The Hill coefficient n can be determined from the Hill plot, ln[y/(19y)] vs lnx, in which the slope at x:xm gives the n value.
Starting from those values estimated graphically, we determined the Hill variables, n and xm, using the least-square fitting of equation (2) to the data points. According to Colosimo, Brunori and Wyman
14
, if the experimental dose-response curve is symmetrical with respect to the half-maximal point x:xm, it follows that: 
We assumed some integer for r (larger than the Hill coefficient n) at first and then obtained other variables from equations (3) and (4) . We attempted to determine the final r value for which the MWC curve, Z:Z(x), fits best to the experimental one through trials with different r values.
IN VIVO DOSE-RESPONSE
The basis of a clinical dose-response curve is essentially different from that of an in vitro, dose-response curve, because the clinical curve is based on statistics of the logit or probit model. Thus we cannot apply the MWC model to the in vivo case by itself. We assume, however, that some log-normal distribution of the in vivo curve, instead of a delta function, against anaesthetic concentration is caused by the difference between individual patients in threshold concentrations required for not responding to surgical incision. First, we assume that all individuals have the same receptor molecules in sufficient concentrations to respond. Second, we assume that such thresholds are determined by fractions of active combined molecules RXi to the total TXi and RXi molecules. In other words, we assume that anaesthetic-sensitive patients do not respond to surgical incision even at low fractions, while nonsensitive patients still respond at high fractions. Using this assumption the dose-response curve derived from our MWC model is consistent with statistics of the univariate binary model. Third, we assume that the anaesthetic concentration is the same as the ligand concentration at receptor sites. Based on these assumptions we apply the MWC model to analyse in vivo and in vitro dose-response data. We consider that the fractional response Z in equation (1) is the percentage of patients not responding to anaesthetics and x is the anaesthetic concentration. 91 in the water phase at 37 ЊC. We then evaluated the three variables in the MWC model using equations (3) and (4) for several r values for GABA ( fig. 1) and for glycine (fig. 2) . In both cases, the MWC curves described well the sigmoidal nature of the experimental dose-response curves, but we could not definitively determine the r values. As seen in reference 9 , more data points are necessary to determine exactly the number of sites r. Among those MWC curves, that for r:2 agreed with its respective Hill curve, and the error sum of squares was smaller for r:2 than for the others in both cases. From these we set r:2 for both cases, and the MWC variables for r:2 and the related Hill variables are listed in table 1.
Results
IN VITRO
We also examined the MWC model for the effect of halothane on the high-threshold component Ca 2; current of clonal (GH3) pituitary cells reported by Herrington and colleagues 11 , as an example of ion channels. The Hill variables were determined as n:1.6 and xm:0.84 mmol litre
91
. It is noted that the half-maximal concentration xm is three or four times larger than the clinical concentration. Figure 3 shows our MWC curves for various r values and their data points. Here we also failed to determine definitively the r value, but the cooperative nature of the experimental curve was expressed well by the MWC model and the Hill approximation. As seen in figure 3 , the MWC curve for r:2 is close to the Hill curve, and the error sum of squares is smaller than for the others. For the same reasons as mentioned above, we set r:2, and the MWC variables are listed in table 1.
IN VIVO DOSE-RESPONSE
Anaesthetic dose-response data in humans were reported by deJong and Eger for halothane 12 , and by Mather, Raftery and Prys-Roberts for isoflurane 13 .
For halothane, figure 4 shows the Hill curves for various n values, where xm:0.75 %atm :0.24 mmol litre
91
, together with the data points 12 . The leastsquare fitting of equation (2) gave xm:0.24 mmol litre 91 and n:27, which is much larger than n:2 for the in vitro results mentioned above. In this case, it was not possible to determine the number of binding sites and it is only possible to note that the r value is an integer more than 27 (see equation (4) Table 1 Hill variables n and xm, and MWC variables KR, KT, c and L, and the number of binding sites r. A was determined from 3 for GABA-induced Cl 9 current (fig. 1) ; B from 3 for glycine-induced CI 9 current (fig. 2) ; C from 11 for Ca 2+ current (fig. 3) ; D from 12 for humans (fig. 4) ; and E from 14 In contrast, the in vivo dose-response curve exhibited a much lesser slope for isoflurane. A least-square fitting of the data points 13 to equation (2) gave the Hill variables as n:3.6 and xm:1.03 %atm. Figure 5 shows the data points and our MWC curve for three r values. The MWC curve for r:4 gave the smallest error sum of squares among the trials with various r values. The MWC variables for r:4 and the Hill variables are listed in table 1.
Discussion
The MWC model describes the nature of the dose-response curve in the electrophysiological experiments for halothane, although the number of binding sites r cannot be determined strictly as yet. If we assume that the fractional response is the percentage of patients not responding to anaesthetics, the MWC model also describes the sigmoidal nature of the clinical dose-response curve for isoflurane. In contrast, the human dose-response curve for halothane is difficult to understand on the basis of the MWC model because of the extremely large value of L.
Mather, Raftery and Prys-Roberts 13 suggested that the steepness of the human dose-response curve obtained by deJong and Eger 12 was apparently enhanced because their sampling method tended to exclude low and high concentrations. For example, the Hill coefficient n, which is a measure of steepness, can be estimated to be 3.6 13 or 8.4 12 for isoflurane. If we assume that such a difference is true proportionally for another anaesthetic, the n value would be reduced from 27 to approximately 10 for halothane. However, it seems that the in vivo curve is steeper than the in vitro curve.
Our in vivo dose-response curve must be governed by the statistics of a univariate binary model on our assumptions. However, its distribution may not agree with the log-normal distribution. In order to check the difference between our distribution and lognormal distribution, we estimated EC50 and EC95 values for isoflurane from our curve. The values obtained were 1.03%atm and 2.36%atm, respectively, which are in agreement with those of Mather, Raftery and Prys-Roberts (EC50:1.00%atm and EC95:2.16%atm) 13 .
Appendix
As mentioned in the text, the MWC model assumes that a receptor molecule has two conformations, R and T, and each form contains r binding sites for a ligand X. The equilibrium scheme of the ligand-receptor system is as follows:
Taking into account the probability factors for the binding of the R and T forms to receptor molecules, we have the following equilibrium equations: 
Equation (1) is defined as the state function 6 7 . rജ2 is the necessary condition of cooperativity, and cooperativity is marked when L is much greater than 1. Figure 5 Anaesthetic potency of isoflurane in humans. The solid curve was obtained from the MWC calculation for r:4; the Hill approximation, n:3.6 and xm:1.03%atm, is on the same solid curve. The broken curves (---and ....... ) are for r:8 and r:12, respectively. Data points were referred to 13 .
